-
EdU Imaging Kits (HF594) for PDAC PNI
2026-09-08
EdU Imaging Kits (HF594) convert S-phase DNA synthesis into a quantitative red-fluorescence readout for pancreatic cancer–Schwann cell models. This article translates the reference study’s PGE2-driven perineural invasion findings into practical imaging, flow cytometry, optimization, and troubleshooting workflows.
-
SHC-1 Inhibition and CFTR Membrane Trafficking
2026-09-08
The 2026 Biochemical and Biophysical Research Communications study shows that MAPK/SHC-1-dependent CFTR internalization occurs across airway and intestinal epithelial models, but that pharmacological responses to SHC-1 inhibitors are strongly cell-context dependent. Its findings refine how researchers interpret CFTR trafficking assays and suggest that increased surface abundance should be distinguished from selective restoration of channel regulation.
-
SM-102 for Reliable mRNA-LNP Cell Assays
2026-09-07
Learn how SM-102 (SKU C1042) can improve the interpretability of cell viability, proliferation, and cytotoxicity workflows involving mRNA-loaded lipid nanoparticles. This scenario-based guide connects formulation identity, solvent compatibility, storage, controls, and vendor selection to evidence from recent mRNA delivery research.
-
XYD113: Selective GSPT1 Degradation in MYC Cancers
2026-09-07
The reference study identifies XYD113 as an orally active molecular glue degrader that selectively recruits CRBN to eliminate GSPT1 in MYC-driven cancer models. Its combination of sub-100 nM cellular antiproliferative activity, limited degradation of common glutarimide substrates, and xenograft efficacy supports further evaluation while leaving important translational questions unresolved.
-
Trelagliptin and PI-3K/AKT Signaling in Adipocytes
2026-09-05
The reference study shows that trelagliptin succinate can improve insulin resistance features in differentiated 3T3-L1 adipocytes by strengthening IRS-1/PI-3K/AKT signaling, GLUT4 membrane localization, and glucose uptake. Its findings extend the interpretation of DPP-4 inhibition beyond glycemic control by connecting trelagliptin with adipokine and lipid-related changes in an adipocyte model.
-
Resveratrol: SIRT1 Activator and Neuroprotection
2026-09-04
Resveratrol is a SIRT1 activator used to study mitochondrial quality control, apoptosis, oxidative stress, and inflammation. Evidence in prion-challenged N2a cells supports a SIRT1–PGC-1α–TFAM mechanism, while product data indicate dose-dependent effects in neuronal and rat cardiac models.
-
CCCP Workflows for Mitochondrial Imaging
2026-09-04
CCCP converts mitochondrial membrane-potential biology into a controlled experimental perturbation for live-cell imaging, morphology analysis, and assay validation. Paired with the urine-derived stem cell and deep-learning strategy reported in the reference study, it helps distinguish baseline disease-associated phenotypes from acute stress responses without overstating biomarker readiness.
-
RIPA Lysis Buffer for BBB Mechanism Translation
2026-09-03
A translational workflow for connecting astrocyte inflammation, blood-brain barrier integrity, and reproducible protein analysis. Using findings from a ginsenoside Rg2 Alzheimer’s disease model, this article explains how lysis chemistry, inhibitor strategy, and assay selection can strengthen mechanistic claims without overstating preclinical evidence.
-
CPSIT_0844 Activates TLR2/TLR4 Inflammation
2026-09-03
This 2026 study identifies the Chlamydia psittaci inclusion membrane protein CPSIT_0844 as a proinflammatory stimulus in human THP-1 monocytes. Its experiments connect CPSIT_0844 to TLR2/TLR4–MyD88 signaling and downstream JNK, p38, and NF-κB activation, clarifying how a pathogen-derived protein may contribute to inflammatory lung disease.
-
Tetracycline C6589 for Reliable Cell Assays
2026-09-02
Learn how Tetracycline (SKU C6589) can support controlled microbiological selection and cleaner interpretation of cell-based viability or proliferation workflows. This scenario-based guide covers mechanism, DMSO compatibility, storage, controls, data interpretation, and practical vendor-selection criteria.
-
Vitamin Repurposing Against SARS-CoV-2: Docking Insights
2026-09-02
Eskandari’s 2022 study used molecular docking and molecular dynamics to evaluate vitamin-derived natural compounds against SARS-CoV-2 3CLpro and the spike receptor-binding domain. The work highlights a dual-target computational strategy for antiviral therapeutics research while showing why predicted binding must be followed by biochemical and cellular validation.
-
Acridine Orange hydrochloride Protocol Guide
2026-09-01
Acridine Orange hydrochloride provides differential fluorescent staining of double-helical and single-stranded nucleic acids for cytochemical workflows, including cell cycle analysis, apoptosis detection, and flow cytofluorometric nucleic acid staining. It is best used as a freshly prepared, validated staining reagent and is not appropriate for long-term solution storage or non-nucleic-acid targets without additional validation.
-
Hoechst 33342 for Hypoxia Vascular Cell Assays
2026-09-01
Hoechst 33342 turns live-cell nuclear labeling into a practical readout for endothelial cell and smooth muscle cell workflows under hypoxia. This guide connects chromatin visualization, cell counting, and nuclear morphology to the SP1/ADAM10/DRP1 study while emphasizing assay controls and troubleshooting.
-
Fluo-4 AM for Podocyte Calcium Assays
2026-08-31
Use Fluo-4 AM to convert rapid intracellular Ca²⁺ changes into actionable data in podocyte, receptor-trafficking, and diabetic nephropathy models. This workflow emphasizes live-cell kinetics, pathway-specific controls, and troubleshooting for reliable calcium signaling assays rather than fluorescence alone.
-
Viral RIPK3 Degradation Drives Inflammation
2026-08-31
Liu et al. identified a viral inducer of RIPK3 degradation, vIRD, that hijacks host SCF ubiquitin-ligase machinery to promote proteasomal destruction of a central necroptosis kinase. Using viral genetics, biochemical assays, and mouse models, the study shows that vIRD reshapes orthopoxvirus replication, inflammation, and mortality through RIPK3–MLKL-dependent pathways.